Meeting
2016 Gastrointestinal Cancers Symposium
REOX: Effectiveness evaluation of re-exposure to oxaliplatin in patients with metastatic colorectal cancer.
Authors
Talita Gonzaga Costa
A.C. Camargo Cancer Center, Sao Paulo, Brazil
Talita Gonzaga Costa , Tiago Cordeiro Felismino , Leonardo de Azevedo Boente , Celso Lopes Mello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 764)
DOI
10.1200/jco.2016.34.4_suppl.764
Abstract #
764
Poster Bd #
N17
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
First Author: Kaori Hayashi
Poster
2014 ASCO Annual Meeting
Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.
First Author: David Chan
Poster
2013 Gastrointestinal Cancers Symposium
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial—Comparison of the efficacy of KRAS status.
First Author: Michio Nakamura
Poster
2023 ASCO Annual Meeting
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).
First Author: William Joseph Chapin